RCS - Arecor Therapeutics - Arecor wins at CambridgeshireLive Business Awards

Arecor TherapeuticsAnnouncement

28/03/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220328:nRSb1371Ga&default-theme=true

RNS Number : 1371G  Arecor Therapeutics PLC  28 March 2022

ARECOR WINS INNOVATION IN BUSINESS AND BUSINESS PERSON OF THE YEAR AWARDS

AT THE CAMBRIDGESHIRELIVE BUSINESS AWARDS

 

Cambridge, UK, 28 March 2022: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical group advancing today's therapies to enable healthier lives,
today announces that Arecor has won the HCR Hewitsons Award for Innovation in
Business, and CEO, Sarah Howell, has won Business Person of the Year at the UK
CambridgeshireLive Business Awards.

 

The CambridgeshireLive Business Awards celebrate and recognise the region's
best business talent, providing companies of all sizes, from pioneering
start-ups to the powerhouses which drive the region's economy a chance to be
recognised and be proud of their achievements.

 

Sarah Howell, Chief Executive Officer of Arecor, said:  "We are delighted to
have won the Award for Innovation in Business, and I am honoured to be
recognised amongst such high-quality candidates leading innovative and dynamic
companies in Cambridge.  Innovation is at the heart of everything we do here
at Arecor as we develop new advanced medicines from today's therapies to
improve the lives of patients.  These awards are an important external
validation of Arecor's strengths and will support us to attract scientific
talent to our growing business."

 

-ENDS-

 

 

For more information, please contact:

 Arecor Therapeutics plc                          www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer         Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com

 Susan Lowther, Chief Financial Officer           Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com

 Mo Noonan, Communications                        Tel: +44 (0) 7876 444977

                                                  Email: mo.noonan@arecor.com

 Panmure Gordon (UK) Limited (NOMAD and Broker)   Tel: +44 (0) 20 7886 2500

 Freddy Crossley, Emma Earl (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Consilium Strategic Communications
 Chris Gardner, David Daley, Angela Gray          Tel: +44 (0) 20 3709 5700

                                                  Email: arecor@consilium-comms.com

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical group
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary formulation technology platform, Arestat™, we are developing an
internal portfolio of proprietary products in diabetes and other indications,
as well as working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The Arestat™
platform is supported by an extensive patent portfolio.

 

For further details please see our website, www.arecor.com
(http://www.arecor.com)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEAXDSADDAEFA